Fbw7γ-mediated degradation of KLF13 prevents RANTES expression in resting human but not murine T lymphocytes

Dong Seok Kim, Wei Zhang, Scott E. Millman, Byung Joon Hwang, Seok Joo Kwon, Carol Clayberger, Michele Pagano, Alan M. Krensky

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

RANTES (CCL5) is a chemokine implicated in many human diseases.We previously showed that the transcription factor Kruppel-like factor 13 (KLF13) controls the late (3-5 days after activation) expression of RANTES in T lymphocytes and that KLF13 itself is translationally regulated through the 5′-untranslated region of its mRNA. Here, we show that KLF13 levels are further regulated by ubiquitination and degradation. KLF13 protein is undetectable in resting human T lymphocytes, but treatment with either proteosomal or lysosomal inhibitors increases KLF13 protein levels. Glycogen synthase kinase 3β (GSK3β)-mediated phosphorylation of KLF13 triggers the ubiquitination of KLF13 by the E3 ligase Fbw7γ, resulting in KLF13 protein degradation. Knockdown of either Fbw7γ or GSK3β by small interfering RNA increases KLF13 expression in resting human T lymphocytes. In contrast, in murine T lymphocytes, KLF13 protein is abundant because of the absence of Fbw7γ. Treatment of unactivated human lymphocytes with lysosomal inhibitors stabilizes KLF13 protein, resulting in an increase of RANTES mRNA and protein. Taken together, these studies found that tightly regulated control of both synthesis and degradation allows rapid changes in the level of KLF13 in human T lymphocytes.

Original languageEnglish (US)
Pages (from-to)1658-1667
Number of pages10
JournalBlood
Volume120
Issue number8
DOIs
StatePublished - Aug 23 2012

Fingerprint

Kruppel-Like Transcription Factors
Chemokine CCL5
T-cells
T-Lymphocytes
Degradation
Glycogen Synthase Kinase 3
Proteins
Ubiquitination
Messenger RNA
Phosphorylation
Transcription factors
Ubiquitin-Protein Ligases
Lymphocytes
5' Untranslated Regions
Chemokines
Small Interfering RNA
Proteolysis

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Kim, D. S., Zhang, W., Millman, S. E., Hwang, B. J., Kwon, S. J., Clayberger, C., ... Krensky, A. M. (2012). Fbw7γ-mediated degradation of KLF13 prevents RANTES expression in resting human but not murine T lymphocytes. Blood, 120(8), 1658-1667. https://doi.org/10.1182/blood-2012-03-415968

Fbw7γ-mediated degradation of KLF13 prevents RANTES expression in resting human but not murine T lymphocytes. / Kim, Dong Seok; Zhang, Wei; Millman, Scott E.; Hwang, Byung Joon; Kwon, Seok Joo; Clayberger, Carol; Pagano, Michele; Krensky, Alan M.

In: Blood, Vol. 120, No. 8, 23.08.2012, p. 1658-1667.

Research output: Contribution to journalArticle

Kim, DS, Zhang, W, Millman, SE, Hwang, BJ, Kwon, SJ, Clayberger, C, Pagano, M & Krensky, AM 2012, 'Fbw7γ-mediated degradation of KLF13 prevents RANTES expression in resting human but not murine T lymphocytes', Blood, vol. 120, no. 8, pp. 1658-1667. https://doi.org/10.1182/blood-2012-03-415968
Kim, Dong Seok ; Zhang, Wei ; Millman, Scott E. ; Hwang, Byung Joon ; Kwon, Seok Joo ; Clayberger, Carol ; Pagano, Michele ; Krensky, Alan M. / Fbw7γ-mediated degradation of KLF13 prevents RANTES expression in resting human but not murine T lymphocytes. In: Blood. 2012 ; Vol. 120, No. 8. pp. 1658-1667.
@article{9232ca2538b240a78ef8f0cc06d74371,
title = "Fbw7γ-mediated degradation of KLF13 prevents RANTES expression in resting human but not murine T lymphocytes",
abstract = "RANTES (CCL5) is a chemokine implicated in many human diseases.We previously showed that the transcription factor Kruppel-like factor 13 (KLF13) controls the late (3-5 days after activation) expression of RANTES in T lymphocytes and that KLF13 itself is translationally regulated through the 5′-untranslated region of its mRNA. Here, we show that KLF13 levels are further regulated by ubiquitination and degradation. KLF13 protein is undetectable in resting human T lymphocytes, but treatment with either proteosomal or lysosomal inhibitors increases KLF13 protein levels. Glycogen synthase kinase 3β (GSK3β)-mediated phosphorylation of KLF13 triggers the ubiquitination of KLF13 by the E3 ligase Fbw7γ, resulting in KLF13 protein degradation. Knockdown of either Fbw7γ or GSK3β by small interfering RNA increases KLF13 expression in resting human T lymphocytes. In contrast, in murine T lymphocytes, KLF13 protein is abundant because of the absence of Fbw7γ. Treatment of unactivated human lymphocytes with lysosomal inhibitors stabilizes KLF13 protein, resulting in an increase of RANTES mRNA and protein. Taken together, these studies found that tightly regulated control of both synthesis and degradation allows rapid changes in the level of KLF13 in human T lymphocytes.",
author = "Kim, {Dong Seok} and Wei Zhang and Millman, {Scott E.} and Hwang, {Byung Joon} and Kwon, {Seok Joo} and Carol Clayberger and Michele Pagano and Krensky, {Alan M.}",
year = "2012",
month = "8",
day = "23",
doi = "10.1182/blood-2012-03-415968",
language = "English (US)",
volume = "120",
pages = "1658--1667",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Fbw7γ-mediated degradation of KLF13 prevents RANTES expression in resting human but not murine T lymphocytes

AU - Kim, Dong Seok

AU - Zhang, Wei

AU - Millman, Scott E.

AU - Hwang, Byung Joon

AU - Kwon, Seok Joo

AU - Clayberger, Carol

AU - Pagano, Michele

AU - Krensky, Alan M.

PY - 2012/8/23

Y1 - 2012/8/23

N2 - RANTES (CCL5) is a chemokine implicated in many human diseases.We previously showed that the transcription factor Kruppel-like factor 13 (KLF13) controls the late (3-5 days after activation) expression of RANTES in T lymphocytes and that KLF13 itself is translationally regulated through the 5′-untranslated region of its mRNA. Here, we show that KLF13 levels are further regulated by ubiquitination and degradation. KLF13 protein is undetectable in resting human T lymphocytes, but treatment with either proteosomal or lysosomal inhibitors increases KLF13 protein levels. Glycogen synthase kinase 3β (GSK3β)-mediated phosphorylation of KLF13 triggers the ubiquitination of KLF13 by the E3 ligase Fbw7γ, resulting in KLF13 protein degradation. Knockdown of either Fbw7γ or GSK3β by small interfering RNA increases KLF13 expression in resting human T lymphocytes. In contrast, in murine T lymphocytes, KLF13 protein is abundant because of the absence of Fbw7γ. Treatment of unactivated human lymphocytes with lysosomal inhibitors stabilizes KLF13 protein, resulting in an increase of RANTES mRNA and protein. Taken together, these studies found that tightly regulated control of both synthesis and degradation allows rapid changes in the level of KLF13 in human T lymphocytes.

AB - RANTES (CCL5) is a chemokine implicated in many human diseases.We previously showed that the transcription factor Kruppel-like factor 13 (KLF13) controls the late (3-5 days after activation) expression of RANTES in T lymphocytes and that KLF13 itself is translationally regulated through the 5′-untranslated region of its mRNA. Here, we show that KLF13 levels are further regulated by ubiquitination and degradation. KLF13 protein is undetectable in resting human T lymphocytes, but treatment with either proteosomal or lysosomal inhibitors increases KLF13 protein levels. Glycogen synthase kinase 3β (GSK3β)-mediated phosphorylation of KLF13 triggers the ubiquitination of KLF13 by the E3 ligase Fbw7γ, resulting in KLF13 protein degradation. Knockdown of either Fbw7γ or GSK3β by small interfering RNA increases KLF13 expression in resting human T lymphocytes. In contrast, in murine T lymphocytes, KLF13 protein is abundant because of the absence of Fbw7γ. Treatment of unactivated human lymphocytes with lysosomal inhibitors stabilizes KLF13 protein, resulting in an increase of RANTES mRNA and protein. Taken together, these studies found that tightly regulated control of both synthesis and degradation allows rapid changes in the level of KLF13 in human T lymphocytes.

UR - http://www.scopus.com/inward/record.url?scp=84865428187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865428187&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-03-415968

DO - 10.1182/blood-2012-03-415968

M3 - Article

VL - 120

SP - 1658

EP - 1667

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -